Mivacron (Mivacurium)

Mivacurium is a non-depolarizing neuromuscular blocking agent used to induce skeletal muscle relaxation during procedures that require controlled ventilation.

• Facilitation of endotracheal intubation: provides rapid, short‑duration paralysis to allow safe placement of the airway tube.
• Muscle relaxation during surgery: maintains a relaxed skeletal musculature throughout general anesthesia for optimal surgical conditions.
• Diagnostic procedures requiring paralysis: enables brief paralysis for certain imaging or electrophysiological studies.

• Mivacurium competitively antagonizes acetylcholine at nicotinic receptors of the neuromuscular junction, preventing depolarization of the motor end‑plate. This blockade inhibits transmission of nerve impulses to skeletal muscle fibers, resulting in a dose‑dependent, short‑acting relaxation of skeletal muscles during intravenous administration.

Mivacurium may cause a range of adverse reactions, from mild to severe, that clinicians monitor during use.

Common Side Effects

• Flushing: transient redness of the skin.
• Hypotension: mild to moderate drop in blood pressure.
• Bronchospasm: narrowing of the airways causing wheezing.
• Injection site pain: discomfort at the site of IV administration.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate intervention.
• Prolonged apnea: extended respiratory paralysis beyond expected duration.
• Malignant hyperthermia: life‑threatening hypermetabolic crisis.
• Cardiac arrest: sudden loss of heart function.
• Severe hypotension: marked drop in blood pressure leading to shock.
• Respiratory depression: inadequate breathing requiring ventilatory support.

When using Mivacron, careful assessment and monitoring are essential to minimize risks.

• Dose adjustment in hepatic impairment: reduce dose as metabolism may be prolonged.
• Avoid in patients with known hypersensitivity to mivacurium or related compounds: discontinue use.
• Monitor neuromuscular function continuously during administration: use a peripheral nerve stimulator.
• Be prepared to manage bronchospasm: have bronchodilators readily available.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that affect neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid)

• Concurrent use of potent cholinesterase inhibitors (e.g., neostigmine) may prolong neuromuscular blockade.
• Combination with other neuromuscular blocking agents can cause additive paralysis.
• Co‑administration with magnesium sulfate may enhance blockade.

Moderate Interactions (Monitor Closely)

• Use with volatile anesthetics may increase duration of action.
• Concurrent use of beta‑adrenergic blockers may affect cardiovascular response.
• Administration alongside antihistamines may mask early signs of an allergic reaction.